A very mild phenotype in six individuals of a three‐generation family with the novel HRAS variant c. 176C > G p.( Ala59Gly ): Emergence of a new HRAS ‐related RASopathy distinct from Costello syndrome
American Journal of Medical Genetics Part A · 2023
DOI: 10.1002/ajmg.a.63240 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2023. Verfasst von Tanja Frey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Genetics, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Costello Syndrome, Noonan Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universität Zürich.
Abstract (Originalsprache)
Costello syndrome is a clinically recognizable, severe neurodevelopmental disorder caused by heterozygous activating variants in HRAS . The vast majority of affected patients share recurring variants affecting HRAS codons 12 and 13 and a relatively uniform phenotype. Here, we report the unique and attenuated phenotype of six individuals of an extended family affected by the HRAS variant c.176C>T p.(Ala59Gly), which, to our knowledge, has never been reported as a germline variant in patients so far. HRAS Alanine 59 has been previously functionally investigated as an oncogenic hotspot and the p.Ala59Gly substitution was shown to impair intrinsic GTP hydrolysis. All six individuals we report share a phenotype of ectodermal anomalies and mild features suggestive of a RASopathy, reminiscent of patients with Noonan syndrome‐like disorder with loose anagen hair. All six are of normal intelligence, none have a history of failure to thrive or malignancy, and they have no known cardiac or neurologic pathologies. Our report adds to the previous reports of patients with rare variants affecting amino acids located in the SWITCH II/G3 region of HRAS and suggests a consistent, attenuated phenotype distinct from classical Costello syndrome. We propose the definition of a new distinct HRAS‐related RASopathy for patients carrying HRAS variants affecting codons 58, 59, 60.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Genetics, University of Zurich, Zurich, Switzerland.
- Department of Dermatology, Pediatric Skin Center, University Children's Hospital Zurich, Zurich, Switzerland.
- University Children's Hospital Zurich, Zurich, Switzerland.
- University of Zurich Research Priority Program ITINERARE: Innovative Therapies in Rare Diseases, Zurich, Switzerland.
- University of Zurich Research Priority Program AdaBD: Adaptive Brain Circuits in Development and Learning, Zurich, Switzerland.
ORCID-Profile: Anita Rauch
Förderung
- Universität Zürich
Zitieren
APA
Frey, T., Ivanovski, I., Bahr, A., Zweier, M., Laube, J., Luchsinger, I., Steindl, K., & Rauch, A. (2023). A very mild phenotype in six individuals of a three‐generation family with the novel HRAS variant c. 176C > G p.( Ala59Gly ): Emergence of a new HRAS ‐related RASopathy distinct from Costello syndrome. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63240
Vancouver
Frey T, Ivanovski I, Bahr A, Zweier M, Laube J, Luchsinger I, et al. A very mild phenotype in six individuals of a three‐generation family with the novel HRAS variant c. 176C > G p.( Ala59Gly ): Emergence of a new HRAS ‐related RASopathy distinct from Costello syndrome. American Journal of Medical Genetics Part A. 2023. doi:10.1002/ajmg.a.63240
BibTeX
@article{Frey2023,
author = {Frey, Tanja and Ivanovski, Ivan and Bahr, Angela and Zweier, Markus and Laube, Julia and Luchsinger, Isabelle and Steindl, Katharina and Rauch, Anita},
title = {A very mild phenotype in six individuals of a three‐generation family with the novel HRAS variant c. 176C > G p.( Ala59Gly ): Emergence of a new HRAS ‐related RASopathy distinct from Costello syndrome},
journal = {American Journal of Medical Genetics Part A},
year = {2023},
doi = {10.1002/ajmg.a.63240}
}
EUVIMED